Low dose IL-2 has also been used in 38 patients with systemic lupus erythematosus (SLE)26 who are considered to have a higher risk of coronary artery disease and therefore cardiac events.34 However, no SAEs were observed while injection site reactions and influenza-like symptoms were observed in 13.2% and 5.3% of patient, respectively.26 The gene discussed is IL2; the disease is systemic lupus erythematosus.